GJA4

GJA4 or Gap Junction Alpha-4 Protein is a protein that in humans is encoded by the GJA4 gene. This protein is also commonly known as Connexin 37 (Cx37). GJA4 is a member of the connexin family, a diverse group of proteins that form gap junctions, allowing for direct communication between cells.

Function[edit | edit source]

GJA4 plays a crucial role in the formation of gap junctions, which are essential for the propagation of electrical signals and the transport of small molecules between cardiac muscle cells, as well as in other tissues including the endothelium. Gap junctions are integral to maintaining the synchronized contraction of the heart and play a role in the regulation of blood pressure and the function of blood vessels.

Gene[edit | edit source]

The GJA4 gene is located on human chromosome 1, specifically at 1p35.1. It spans approximately 8.5 kilobases and consists of 2 exons. The gene's expression is regulated by various physiological and pathological conditions, indicating its importance in diverse biological processes and its potential involvement in disease.

Clinical Significance[edit | edit source]

Alterations in the expression or function of GJA4 have been implicated in several cardiovascular diseases, including atherosclerosis, hypertension, and heart disease. Mutations in the GJA4 gene or dysregulation of Connexin 37 expression can lead to impaired gap junction communication, contributing to the pathogenesis of these conditions.

Research has also suggested a role for GJA4 in the regulation of endothelial function and angiogenesis, the process by which new blood vessels form from pre-existing vessels. This is particularly relevant in the context of wound healing and the development of certain types of cancer, where angiogenesis plays a critical role.

Potential Therapeutic Target[edit | edit source]

Given its involvement in critical physiological processes and various diseases, GJA4 represents a potential target for therapeutic intervention. Modulating the function or expression of Connexin 37 could offer new avenues for the treatment of cardiovascular diseases and disorders associated with impaired angiogenesis.